(ISRG) Intuitive Surgical - Ratings and Ratios
Surgical Systems, Diagnostic Equipment, Instrumentation, Support Services
ISRG EPS (Earnings per Share)
ISRG Revenue
Description: ISRG Intuitive Surgical
Intuitive Surgical Inc. is a pioneering medical technology company that enables healthcare providers to deliver high-quality, minimally invasive care. The companys flagship product, the da Vinci Surgical System, has revolutionized the field of surgery, while its Ion endoluminal system has expanded its offerings into diagnostic procedures. With a comprehensive suite of instrumentation, services, and digital capabilities, Intuitive Surgical supports the adoption and effective use of its technology.
Key performance indicators (KPIs) that demonstrate the companys success include its growing revenue and installed base of da Vinci systems, as well as its expanding customer support infrastructure. The companys commitment to innovation is reflected in its significant R&D investments, which have enabled the development of new products and features. ISRGs financials indicate a strong track record of growth, with a market capitalization of over $183 billion and a return on equity (ROE) of 15.52%. The companys valuation multiples, such as its P/E ratio of 75.19, suggest a premium valuation, likely due to its dominant market position and growth prospects.
From a competitive standpoint, Intuitive Surgicals leadership in the robotic-assisted surgery market is evident, with a strong brand and a large installed base. The companys focus on expanding its offerings into new areas, such as diagnostic procedures, and enhancing its digital capabilities, positions it for continued growth. As the healthcare industry continues to evolve towards more minimally invasive and data-driven care, Intuitive Surgical is well-positioned to capitalize on these trends.
ISRG Stock Overview
| Market Cap in USD | 163,412m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2000-06-13 |
ISRG Stock Ratings
| Growth Rating | 43.7% |
| Fundamental | 80.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -25.7% |
| Analyst Rating | 4.03 of 5 |
ISRG Dividends
Currently no dividends paidISRG Growth Ratios
| Growth Correlation 3m | -91.2% |
| Growth Correlation 12m | -22.9% |
| Growth Correlation 5y | 73.3% |
| CAGR 5y | 29.30% |
| CAGR/Max DD 3y | 1.01 |
| CAGR/Mean DD 3y | 5.92 |
| Sharpe Ratio 12m | 0.43 |
| Alpha | -30.81 |
| Beta | 0.910 |
| Volatility | 42.91% |
| Current Volume | 3474.8k |
| Average Volume 20d | 2024.2k |
| Stop Loss | 420.9 (-3%) |
| Signal | -1.67 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (2.61b TTM) > 0 and > 6% of Revenue (6% = 548.7m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 7.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 77.13% (prev 81.44%; Δ -4.31pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 2.83b > Net Income 2.61b (YES >=105%, WARN >=100%) |
| Net Debt (-3.40b) to EBITDA (3.26b) ratio: -1.04 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (364.1m) change vs 12m ago 0.86% (target <= -2.0% for YES) |
| Gross Margin 66.65% (prev 66.86%; Δ -0.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 49.68% (prev 45.48%; Δ 4.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 30.12 (EBITDA TTM 3.26b / Interest Expense TTM 90.4m) >= 6 (WARN >= 3) |
Altman Z'' 8.13
| (A) 0.35 = (Total Current Assets 8.75b - Total Current Liabilities 1.69b) / Total Assets 20.16b |
| (B) 0.38 = Retained Earnings (Balance) 7.61b / Total Assets 20.16b |
| (C) 0.15 = EBIT TTM 2.72b / Avg Total Assets 18.41b |
| (D) 3.44 = Book Value of Equity 7.61b / Total Liabilities 2.21b |
| Total Rating: 8.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.69
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 1.24% = 0.62 |
| 3. FCF Margin 21.81% = 5.45 |
| 4. Debt/Equity 0.12 = 2.49 |
| 5. Debt/Ebitda 0.68 = 2.15 |
| 6. ROIC - WACC 4.92% = 6.15 |
| 7. RoE 15.57% = 1.30 |
| 8. Rev. Trend 96.85% = 7.26 |
| 9. EPS Trend 95.18% = 4.76 |
What is the price of ISRG shares?
Over the past week, the price has changed by -7.66%, over one month by -9.63%, over three months by -16.39% and over the past year by -11.68%.
Is Intuitive Surgical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ISRG is around 419.32 USD . This means that ISRG is currently overvalued and has a potential downside of -3.38%.
Is ISRG a buy, sell or hold?
- Strong Buy: 14
- Buy: 8
- Hold: 10
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the ISRG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 582.1 | 34.1% |
| Analysts Target Price | 582.1 | 34.1% |
| ValueRay Target Price | 470.9 | 8.5% |
Last update: 2025-09-13 04:37
ISRG Fundamental Data Overview
CCE Cash And Equivalents = 5.33b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 63.6662
P/E Forward = 49.2611
P/S = 17.869
P/B = 9.1569
P/EG = 2.8636
Beta = 1.617
Revenue TTM = 9.14b USD
EBIT TTM = 2.72b USD
EBITDA TTM = 3.26b USD
Long Term Debt = 517.5m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.69b USD (from totalCurrentLiabilities, last quarter)
Debt = 2.21b USD (Calculated: Short Term 1.69b + Long Term 517.5m)
Net Debt = -3.40b USD (from netDebt column, last quarter)
Enterprise Value = 160.30b USD (163.41b + Debt 2.21b - CCE 5.33b)
Interest Coverage Ratio = 30.12 (Ebit TTM 2.72b / Interest Expense TTM 90.4m)
FCF Yield = 1.24% (FCF TTM 1.99b / Enterprise Value 160.30b)
FCF Margin = 21.81% (FCF TTM 1.99b / Revenue TTM 9.14b)
Net Margin = 28.51% (Net Income TTM 2.61b / Revenue TTM 9.14b)
Gross Margin = 66.65% ((Revenue TTM 9.14b - Cost of Revenue TTM 3.05b) / Revenue TTM)
Tobins Q-Ratio = 21.07 (Enterprise Value 160.30b / Book Value Of Equity 7.61b)
Interest Expense / Debt = 4.09% (Interest Expense 90.4m / Debt 2.21b)
Taxrate = 12.58% (336.3m / 2.67b)
NOPAT = 2.38b (EBIT 2.72b * (1 - 12.58%))
Current Ratio = 5.17 (Total Current Assets 8.75b / Total Current Liabilities 1.69b)
Debt / Equity = 0.12 (Debt 2.21b / last Quarter total Stockholder Equity 17.85b)
Debt / EBITDA = 0.68 (Net Debt -3.40b / EBITDA 3.26b)
Debt / FCF = 1.11 (Debt 2.21b / FCF TTM 1.99b)
Total Stockholder Equity = 16.74b (last 4 quarters mean)
RoA = 12.93% (Net Income 2.61b, Total Assets 20.16b )
RoE = 15.57% (Net Income TTM 2.61b / Total Stockholder Equity 16.74b)
RoCE = 15.77% (Ebit 2.72b / (Equity 16.74b + L.T.Debt 517.5m))
RoIC = 14.22% (NOPAT 2.38b / Invested Capital 16.74b)
WACC = 9.29% (E(163.41b)/V(165.62b) * Re(9.37%)) + (D(2.21b)/V(165.62b) * Rd(4.09%) * (1-Tc(0.13)))
Shares Correlation 3-Years: 76.93 | Cagr: 0.09%
Discount Rate = 9.37% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 68.82% ; FCFE base≈1.36b ; Y1≈1.07b ; Y5≈691.6m
Fair Price DCF = 28.97 (DCF Value 10.38b / Shares Outstanding 358.5m; 5y FCF grow -26.02% → 3.0% )
EPS Correlation: 95.18 | EPS CAGR: 24.83% | SUE: 2.20 | # QB: True
Revenue Correlation: 96.85 | Revenue CAGR: 17.73%
Additional Sources for ISRG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle